162 related articles for article (PubMed ID: 33183271)
21. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
Jones RP; Sutton PA; Evans JP; Clifford R; McAvoy A; Lewis J; Rousseau A; Mountford R; McWhirter D; Malik HZ
Br J Cancer; 2017 Mar; 116(7):923-929. PubMed ID: 28208157
[TBL] [Abstract][Full Text] [Related]
22. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
23. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
24.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
25. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
[TBL] [Abstract][Full Text] [Related]
26. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
27. Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients.
Gorukmez O; Yakut T; Gorukmez O; Sag SO; Karkucak M; Kanat O
Asian Pac J Cancer Prev; 2016; 17(3):1175-9. PubMed ID: 27039744
[TBL] [Abstract][Full Text] [Related]
28. Construction of prediction model for KRAS mutation status of colorectal cancer based on CT radiomics.
Cao Y; Zhang J; Huang L; Zhao Z; Zhang G; Ren J; Li H; Zhang H; Guo B; Wang Z; Xing Y; Zhou J
Jpn J Radiol; 2023 Nov; 41(11):1236-1246. PubMed ID: 37311935
[TBL] [Abstract][Full Text] [Related]
29. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.
Nakanishi R; Harada J; Tuul M; Zhao Y; Ando K; Saeki H; Oki E; Ohga T; Kitao H; Kakeji Y; Maehara Y
Int J Clin Oncol; 2013 Dec; 18(6):1042-8. PubMed ID: 23188063
[TBL] [Abstract][Full Text] [Related]
30. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
31. Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.
Li ZZ; Bai L; Wang F; Zhang ZC; Wang F; Zeng ZL; Zeng JB; Zhang DS; Wang FH; Wang ZQ; Li YH; Shao JY; Xu RH
Med Oncol; 2016 Jul; 33(7):71. PubMed ID: 27270901
[TBL] [Abstract][Full Text] [Related]
32. Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
Kim ST; Chang WJ; Jin L; Sung JS; Choi YJ; Kim YH
Cancer Res Treat; 2015 Oct; 47(4):796-803. PubMed ID: 25687873
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
34. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.
Inamura K; Song M; Jung S; Nishihara R; Yamauchi M; Lochhead P; Qian ZR; Kim SA; Mima K; Sukawa Y; Masuda A; Imamura Y; Zhang X; Pollak MN; Mantzoros CS; Harris CC; Giovannucci E; Fuchs CS; Cho E; Chan AT; Wu K; Ogino S
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598515
[TBL] [Abstract][Full Text] [Related]
35. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
Yarom N; Gresham G; Boame N; Jonker D
Clin Colorectal Cancer; 2019 Dec; 18(4):e309-e315. PubMed ID: 31547963
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
37. [KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].
Zhu XL; Cai X; Zhang L; Yang F; Sheng WQ; Lu YM; Du X; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):584-9. PubMed ID: 23157824
[TBL] [Abstract][Full Text] [Related]
38. Clinical Predictors for KRAS Codon 13 Mutations in Patients With Colorectal Cancer.
Kwak MS; Cha JM; Cho YH; Kim SH; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
J Clin Gastroenterol; 2018; 52(5):431-436. PubMed ID: 28277374
[TBL] [Abstract][Full Text] [Related]
39. Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients.
Li Z; Chen Y; Wang D; Wang G; He L; Suo J
J Int Med Res; 2012; 40(4):1589-98. PubMed ID: 22971512
[TBL] [Abstract][Full Text] [Related]
40. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
